X

Trial Profile

A phase 3 study of BXCL501 to evaluate safety and collect additional efficacy data in at-home setting

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Agitation
Focus Therapeutic Use
Acronyms TRANQUILITY At Home

Most Recent Events

12 Mar 2024 According to a BioXcel Therapeutics media release, Company is re-evaluating the timing for initiating TRANQUILITY At Home.
13 Feb 2024 According to a BioXcel Therapeutics media release, the Company intends to focus on its upcoming meeting with the FDA on February 20, 2024 for its Phase 3 TRANQUILITY At Home trial. The data readout from this trial is expected in Q1 2025.
11 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com